Methods for identifying and using IKK inhibitors

Abstract

The present invention provides methods and compositions for inhibiting IKK, as well as methods and compositions for identifying compounds with activity as inhibitors of IKK, and methods and compositions for the treatment of diseases and/or conditions wherein IKK is implicated and inhibition of its activity is desired. In addition, the present invention provides methods and compositions for the improving the therapeutic activity of COX2 inhibitors, comprising administering the COX2 to a subject in combination with a compound that inhibits IKK activity. The present invention further provides compositions that comprise compounds that inhibit IKK and COX2.

1 - 21 . (canceled) 
     
     
         22 . A method to prevent disease associated with NFκB, comprising:
 a) providing:
 i) an animal at risk for disease associated with NFκB, and wherein said animal expresses IKK, and 
 ii) a composition that inhibits IKK; and 
   b) administering said compound to said animal under conditions such that said composition inhibits IKK expressed by said animal, resulting in inhibition of NFκB.   
     
     
         23 . The method of  claim 22 , wherein said animal is a human. 
     
     
         24 . The method of  claim 22 , wherein said composition comprises a compound that interacts with cysteine-179 of said IKK. 
     
     
         25 . The method of  claim 22 , wherein said disease is selected from the group consisting of inflammation, cancer, bacterial, and viral diseases. 
     
     
         26 . The method of  claim 22 , wherein said composition comprises at least one cyclopentenone. 
     
     
         27 . The method of  claim 26 , wherein said cyclopentenone is a cyclopentenone prostaglandin. 
     
     
         28 - 30 . (canceled) 
     
     
         31 . A method to treat disease associated with NFκB, comprising:
 a) providing:
 i) an animal having at least one disease associated with NFκB, and wherein said animal expresses IKK, and 
 ii) a composition that inhibits IKK; and 
   b) administering said compound to said animal under conditions such that said composition inhibits IKK expressed by said animal, resulting in inhibition of NFκB.   
     
     
         32 . The method of  claim 31 , wherein said animal is a human. 
     
     
         33 . The method of  claim 31 , wherein said composition comprises a compound that interacts with cysteine-179 of said IKK. 
     
     
         34 . The method of  claim 31 , wherein said disease is selected from the group consisting of inflammation, cancer, bacterial and viral diseases. 
     
     
         35 . The method of  claim 31 , wherein said composition comprises at least one cyclopentenone. 
     
     
         36 . The method of  claim 35 , wherein said cyclopentenone is a cyclopentenone prostaglandin.